MoonLake’s Sonelokimab Achieves High Response Rates in HS After 12 Months
Sonelokimab shows strong 1-year results in HS, with many patients seeing clear skin, less pain, and better quality of life, with good safety.
/ 1649 items
#XY↓
Butterfly Network Soars as Midjourney Enters Medical Imaging with Revolutionary Full-Body Ultrasound Scanner
AI-powered 60-second scans could transform preventive healthcare.
Pfizer Announces Departure of CFO Dave Denton, Names Interim Successor
Cecile Guegan named Interim CFO as the company reaffirms its 2026 guidance.
Novocure Stock Plunges After Phase 3 TRIDENT Study Fails to Meet Primary Goal
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
Wall Street Initiates Coverage on IMMX, PRAX & RNA with Buy Ratings – Morgan Stanley Downgrades ENGN
BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
The deal adds multiple early-stage small-molecule immunology assets to Biogen’s pipeline, with the lead candidate entering Phase 1 in Q3 2026.